Hannover Medical School spinout Cardior has welcomed both new and existing backers, such as Bristol Myers Squibb, for a series B round led by Inkef Capital.
Cardior Pharmaceuticals, a Germany-based developer of therapeutics for cardiac diseases based on research at Hannover Medical School, closed a €64m ($76m) series B round today led by venture capital firm Inkef Capital.
Pharmaceutical firm Bristol Myers Squibb (BMS) took part in the round together with Fund+, Sunstone, Hadean Ventures, Coparion, LSP, BioMedPartners and High-Tech Gründerfonds (HTGF).
Founded in 2016, Cardior Pharmaceuticals is working on non-coding RNA-based therapeutics that would be capable of preventing, repairing and reversing heart diseases by addressing the root causes rather than treating symptoms.
The series B capital has been allocated to the late-stage development of Cardior’s lead asset, CDR132L, which targets micro-RNA-132 whose dysregulation contributes to the occurrence of several conditions.
Cardior completed a $16.5m series A round co-led by BMS and its peer Boehringer Ingelheim, which invested through its Boehringer Ingelheim Venture Fund, in 2017. HTGF and BioMedPartners participated in…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
